Table 1.
Patients’ characteristics according to BCL-2 expression.
| BCL-2+ (n = 81) | BCL-2- (n = 32) | p | |
|---|---|---|---|
| Median age (range), years | 73 (65–85) | 74 (65–83) | 0.85 |
| AML type | 0.15 | ||
| De novo | 31 | 17 | |
| Secondary | 50 | 15 | |
| Mean WBC (IQR), ×109/L | 6.6 (4.3–9.5) | 8.5 (4.0–33.0) | 0.048 |
| ELN cytogenetic/molecular risk | 0.045 | ||
| Favorable | 11 | 6 | |
| Intermediate | 29 | 18 | |
| Unfavorable | 41 | 8 | |
| FLT3 | 0.96 | ||
| ITD/TKD | 13 | 5 | |
| WT | 68 | 27 | |
| NPM | 0.31 | ||
| Mutated | 13 | 4 | |
| WT | 67 | 26 | |
| NA | 1 | 2 | |
| CD34 | 0.90 | ||
| Positive | 65 | 26 | |
| Negative | 16 | 6 | |
| CD56 | 0.09 | ||
| Positive | 22 | 14 | |
| Negative | 59 | 18 |
AML: acute myeloid leukemia; WBC: white blood cell; IQR: interquartile range; ELN: European Leukemianet; WT: wild type; NPM: Nucleophosmin; NA: not available.